BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J, Lee K, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 2016;36:635-43. [DOI: 10.1089/jir.2015.0173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ji F, Zhou R, Wang W, Bai D, He C, Cai Z, Shen Y, Wang S, Deng H, Li Z. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy. Journal of Interferon & Cytokine Research 2017;37:362-8. [DOI: 10.1089/jir.2017.0040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
2 Broggi A, Granucci F, Zanoni I. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J Exp Med 2020;217:e20190295. [PMID: 31821443 DOI: 10.1084/jem.20190295] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 22.0] [Reference Citation Analysis]
3 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
4 Wang X, Wang H, Liu MQ, Li JL, Zhou RH, Zhou Y, Wang YZ, Zhou W, Ho WZ. IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol 2017;8:210. [PMID: 28321215 DOI: 10.3389/fimmu.2017.00210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
5 Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina J, Xu D, Srinivasan S, Portsmouth S. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research 2017;37:103-11. [DOI: 10.1089/jir.2016.0082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
6 Bruening J, Weigel B, Gerold G. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res 2017;2017:7232361. [PMID: 28255563 DOI: 10.1155/2017/7232361] [Cited by in F6Publishing: 14] [Reference Citation Analysis]